Showing results (111-120 of 410) with videos related to
Sort By:
Pageof 41
Journal for Immunotherapy of Cancer|April 19, 2020
C reactive protein impairs adaptive immunity in immune cells of patients with melanomaTatsuya Yoshida, Junya Ichikawa, Iulia Giuroiu, et al.Journal of the National Cancer Institute|September 10, 2010
Improved endpoints for cancer immunotherapy trialsAxel Hoos, Alexander M M Eggermont, Sylvia Janetzki, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 24, 2024
Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized PatientsMichael Li, Danny Wong, Jordan S Sack, et al.Cancer Immunology Research|May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanomaF Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.Journal for Immunotherapy of Cancer|August 16, 2017
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case seriesDylan J Martini, Aly-Khan A Lalani, Dominick Bossé, et al.Cancer Immunology Research|January 13, 2019
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in MelanomaErik Yusko, Marissa Vignali, Richard K Wilson, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|December 6, 2016
Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunityScott C Bresler, Le Min, Scott J Rodig, et al.Journal for Immunotherapy of Cancer|March 30, 2019
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibitionGirish S Naik, Sushrut S Waikar, Alistair E W Johnson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaDirk Schadendorf, F Stephen Hodi, Caroline Robert, et al.Journal for Immunotherapy of Cancer|March 8, 2018
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patientsPriyanka B Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, et al.Pageof 41